This robust WOCF analysis strengthens the clinical case for verekitug by accounting for real-world rescue therapy use, increasing confidence in its efficacy. Traders should monitor upcoming regulatory discussions and Phase 3 trial initiation as key catalysts. The every-12-week dosing could offer a competitive advantage over existing biologics.
Price Chart
Executive Summary
Upstream Bio released additional Phase 2 VIBRANT trial data for verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP), showing statistically significant improvement in the primary endpoint (NPS reduction of -1.95, p < 0.0001) using a worst-observation carried-forward (WOCF) analysis that accounts for rescue therapy. The results reinforce prior top-line data and support advancement into Phase 3 trials for CRSwNP and severe asthma.
Key Facts
- Verekitug demonstrated a placebo-adjusted reduction in nasal polyp score (NPS) of -1.95 (p < 0.0001) in WOCF analysis, stronger than the primary analysis (-1.77).
- Secondary endpoint showed -0.96 improvement in nasal congestion score (NCS, p < 0.0001), also stronger than primary analysis.
- Verekitug reduced need for surgery or systemic corticosteroids by 76% (p = 0.03) vs placebo.
- Favorable safety profile with no serious adverse events (SAEs) observed.
- Company plans to initiate Phase 3 trials in CRSwNP and severe asthma following regulatory interactions.
Financial Impact
Potential blockbuster-level commercial upside if Phase 3 success and approval achieved; current market cap of $415M may not reflect late-stage potential.
Risk Factors
- Phase 3 trial results may not replicate Phase 2 efficacy.
- Regulatory authorities may require additional studies or different endpoints.
- Competition from established biologics (e.g., dupilumab, tezepelumab) and upcoming TSLP-targeting agents.
- Company may need to raise capital, leading to dilution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3246934 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 8w ago | 8-K | $6.55 | awaiting T+60 | — | $2.84 (−56.72%) |
Aug 11, 2026 11w ago | 8-K | $7.44 | awaiting T+60 | — | $2.84 (−61.90%) |
Jun 17, 2026 18w ago | Insider Cluster | $6.25 | awaiting T+60 | — | $2.84 (−54.64%) |
Jun 14, 2026 19w ago | Press Release | $6.10 $5.96 | ▼ −2.30% | ▼ −3.30% | $2.84 (−53.52%) |
May 18, 2026 23w ago | Press Release | $8.51 $6.91 | ▼ −18.80% | ▼ −23.65% | $2.84 (−66.69%) |
May 13, 2026 23w ago | Press Release | $9.36 $7.25 | ▲ +22.54% | ▲ +26.98% | $2.84 (+69.71%) |
Apr 17, 2026 27w ago | Press Release | $9.99 $7.14 | ▼ −28.53% | ▼ −34.67% | $2.84 (−71.62%) |
Mar 26, 2026 30w ago | 424B5 | $8.67 $6.41 | ▲ +26.07% | ▲ +42.13% | $2.84 (+67.30%) |
Mar 26, 2026 30w ago | Press Release | $9.79 $6.40 | ▼ −34.68% | ▼ −48.63% | $2.84 (−71.04%) |
Mar 16, 2026 32w ago | Insider Cluster | $9.61 $6.45 | ▼ −32.88% | ▼ −43.37% | $2.84 (−70.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers